- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03591822
Pilot Study of a Robot-assisted Intervention for the Management of Care-induced Pain in Dementia (PARODOL)
Prevention of Care-induced Pain in Elderly Persons With Cognitive Impairments and Living in EHPAD : Systematic Evaluation and Mediation With the PARO Robot.
Health care professionals lack tools to deal with acute pain in patients with moderate to severe dementia during daily nursing situations. Care-induced pain in institutionalized persons with cognitive impairments can cause anxiety and behavioral problems.The aim of this study is to demonstrate that a systematic identification of pain associated with the use of social robots such as the PARO robot may contribute to a better anticipation and management of care-induced pain. The investigators hypothesize that an individual use of the PARO robot would bring relaxation to the patient, a distraction regarding the aversive situation of care and, thus, it would prevent manifestations of acute pain in patients with dementia.
Secondary objectives of the study :
- determine the effect of the use of PARO during painful cares on quality of life, medication of patients, and perceived workload of the health-care team.
- examine socio-demographic and clinical responders' participants to the intervention, and,
- identify essential elements regarding cost-effectiveness of a systematic evaluation of pain and a mediation with the PARO robot in care-induced pain
Study Overview
Status
Conditions
Detailed Description
in is a frequent problem in persons with moderate to severe dementia and has been associated to different care situations. Daily observations in care homes show that pain frequently causes anxiety and behavioral symptoms, including agitation and opposition to nursing care. A key recommendation of the International Psychogeriatric Association (IPA) is the use of psychosocial approaches as first-line therapy for behavioral problems in persons with dementia. Indeed, a wide range of non-pharmacological interventions for persons with dementia exist, such as biofeedback, music therapy, therapeutic touch or relaxation. Most of these interventions have shown positive results on health status, quality of life, socialization, and functional capacity in dementia. However, to date, little is known on the effect of psychosocial interventions on care-induced pain in this population. In consequence, there is still a need for the development of innovative interventions.
At a time when modern technologies are assuming a central role in our society, investigators are currently witnessing an important evolution of the use of social robots in healthcare interventions. In this research area, numerous studies have been conducted with social robots, such as PARO®, an animal-like robot modeled on a baby harp seal. Most of them have been successful in encouraging communication and/or social behaviors and also reducing Behavioral and Psychological Symptoms of Dementia (BPSD), loneliness, stress' levels, agitation and the use of pain medication. However, although these results indicate a potential application of robot-assisted therapies for pain management in persons with dementia, the use of PARO during painful care-situations is still to be investigated.
The investigators propose a new combination of current health cares, namely to mediate care-induced pain with the PARO robot.
Consequently, a randomized AB/BA crossover design will be employed. Patients will be assigned randomly to either phase A during which they will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator, followed by phase B during which patients will benefit from a systemic pain assessment without the PARO robot, or phase B followed by phase A.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bellegarde-en-Forez, France, 42210
- Résidence Mutualiste " L'adret "
-
La Grand-Croix, France, 43320
- Résidence Mutualiste " Les Tilleuls "
-
Paris, France, 75013
- Hopital BROCA
-
Saint-Etienne, France, 42000
- Résidence Mutualiste " La Cerisaie "
-
Saint-Just-Malmont, France, 43240
- Résidence Mutualiste " Marie Lagrevol "
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient over 60 years of age
- Consent to participate
- Patient diagnosed by a geriatrician or a neurologist with moderate to severe dementia (MMSE<24), according to the criteria of the Diagnostic and Statistical Manual DSM IV-TR (APA,2004) and NINCDS-ADRDA(McKhann et al.1984).
- Patient living in a nursing home or a long stay department
- Painful patient during nursing care (pain drugs prescription or direct observation)
Exclusion Criteria:
- Patient (or patient's legal representative) does not provide consent
- The presence of acute organic disease or psychiatric decompensation and major neuropsychiatric symptoms incompatible with the intervention.
- Patient who cannot interact physically with Paro
- The presence of multidrug-resistant bacteria in patient to reduce the risk of contamination.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Arm AB : Intervention under study x Control intervention
Subjects receive intervention A during which they will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator, followed by intervention B during which patients will benefit from a systemic pain assessment without the PARO robot.
|
Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.
A systematic evaluation of the pain
|
|
Other: Arm BA: Control intervention x Intervention under study
Subjects receive intervention B during which they will benefit from a systemic pain assessment without the PARO robot, followed by intervention A during which patients will benefit from a systemic pain assessment and from the PARO robot as a therapeutic mediator.
|
Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.
A systematic evaluation of the pain
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ALGOPLUS scale
Time Frame: 2 months
|
A proximal measure of pain rating on a scale of 1) facial expressions, 2) look, 3) complaints, 4) body position and, 5) atypical behaviors. And a distal measures of pain |
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PACSLAC-F score
Time Frame: at inclusion
|
A distal measure of pain .
|
at inclusion
|
|
PACSLAC-F score
Time Frame: 4 weeks
|
A distal measure of pain .
|
4 weeks
|
|
PACSLAC-F score
Time Frame: 8 weeks
|
A distal measure of pain .
|
8 weeks
|
|
Simple verbal scale (SVS)
Time Frame: 2 months
|
Measurement with a scale in 3 points
|
2 months
|
|
The appreciation of the Paro robot
Time Frame: 2 months
|
Measurement with a visual scale in 5 points: from 1 (not at all) to 5 (considerably) on a visual scale.
|
2 months
|
|
Incidence of patient Medication
Time Frame: 2 months
|
Medications (analgesic, neuroleptic, anxiolytic, antidepressant, sleeping pill) taken by the patient
|
2 months
|
|
EQ-5D score
Time Frame: at inclusion
|
A questionnaire (EQ-5D) of quality life which includes five single-item dimensions assessing: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression of participants.
|
at inclusion
|
|
EQ-5D score
Time Frame: 4 weeks
|
A questionnaire (EQ-5D) of quality life which includes five single-item dimensions assessing: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression of participants.
|
4 weeks
|
|
EQ-5D score
Time Frame: 8 weeks
|
A questionnaire (EQ-5D) of quality life which includes five single-item dimensions assessing: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression of participants.
|
8 weeks
|
|
Appreciation of care
Time Frame: 2 months
|
Measurement with 2 visual scales in 4 and 5 points
|
2 months
|
|
Appreciation of PARO robot
Time Frame: 2 months
|
Measurement with a visual scale in 5 points
|
2 months
|
|
Duration of the care
Time Frame: 2 months
|
2 months
|
|
|
NASA-TLX score
Time Frame: 2 months
|
The NASA-TLX is an instrument to assess overall subjective workload with 6 dimensions of "workload" experienced by the health-care team: Mental Demand, Physical Demand and Temporal Demand, Frustration, Effort, and Performance
|
2 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Anne-Sophie RIGAUD, MD, PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K170608J
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate to Severe Dementia
-
Beer, Kenneth R., M.D., PAMedicis Pharmaceutical CorporationCompletedMild to Moderate Temporal Atrophy | Moderate to Severe Glabellar Rhytids | Moderate to Severe Periorbital RhytidsUnited States
-
Nanjing RegeneCore Biotech Co., Ltd.Not yet recruiting
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.RecruitingModerate to Severe AsthmaChina
-
IpsenRecruitingModerate to Severe Glabellar LinesUnited States, Germany, France, Japan
-
Shanghai Longwood Biopharmaceuticals Co., Ltd.Tigermed Consulting Co., LtdNot yet recruitingModerate to Severe Atopic DermatitisChina
-
Qilu Pharmaceutical Co., Ltd.Not yet recruitingModerate-to-severe Atopic Dermatitis
-
Croma-Pharma GmbHCompleted
-
JHM BioPharma (Tonghua) Co. , Ltd.Completed
-
Chongqing Claruvis Pharmaceutical Co., Ltd.Active, not recruiting
-
AbbVieCompletedModerate to Severe Glabellar LinesJapan
Clinical Trials on A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot
-
Fondation LenvalRecruiting
-
Rennes University HospitalRecruiting
-
University Hospital, MontpellierCompletedAttention Deficit Disorder | Emotional DysfunctionFrance
-
University Hospital, MontpellierCompleted
-
University Hospital, Strasbourg, FranceTerminatedKeratitis | Pterygium | Corneal Perforation | Corneal Opacity Corneal ThinningFrance
-
University Hospital, ToulouseNot yet recruiting
-
University of RzeszowDonum Corde Rehabilitation CenterNot yet recruitingNervous System Diseases | Physical Activity | Neurorehabilitation | Biomedical Enhancement
-
Centre hospitalier de l'Université de Montréal...Completed
-
Centre Hospitalier Universitaire de NīmesWithdrawn
-
Dokuz Eylul UniversityCompletedMucositis | Pediatric Cancer | Oral CavityTurkey